Patient description: A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Sleep Initiation and Maintenance Disorders A female subject of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study Has a body mass index between 18 and 34, inclusive Based on sleep history, the subject has had chronic insomnia for at least 3 months, as defined by the following The predominant complaint is difficulty initiating or maintaining sleep, or non-restorative sleep, for at least 3 months The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning The sleep disturbance does not occur exclusively during the course of narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, or parasomnia The disturbance does not occur exclusively during the course of another mental disorder (eg, major depressive disorder, generalized anxiety disorder, delirium) The disturbance is not due to the direct physiological effects of a substance or a general medical condition Based on sleep history, the subject reports a history of subjective sleep latency ≥45 minutes and a subjective total sleep time ≤6.5 hours for at least 3 months Based on sleep history, the subject's habitual bedtime is between 10:00 PM and 1:00 AM  Has a known hypersensitivity to ramelteon or related compounds, including melatonin Has participated in a study involving ramelteon within 6 months of initial Screening Visit Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the first night of single-blind study medication Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of single-blind study medication, or has flown across greater than 3 time zones within 7 days prior to Screening Has participated in a weight loss program or has substantially altered his or her exercise routine within 30 days prior to the first night of single-blind study medication Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movements during sleep, chronic obstructive pulmonary disease, fibromyalgia, schizophrenia, bipolar disorder, mental retardation or a cognitive disorder Has a history of psychiatric disorder (including anxiety or depression) within the past 12 months Has a history of drug addiction or alcohol abuse and/or regularly consumes 4 or more alcoholic drinks per day within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised Has a current significant neurological (including cognitive and psychiatric disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to the first night of single blind study medication The subject uses tobacco products (including nicotine gum and patch) during nightly awakenings